After two years characterized by layoffs, pipeline reorganizations, FDA delays and clinical holds, Novavax CEO John Jacobs ...

As I have documented in some >20+ articles over ~ten years, Novavax is a struggling clinical phase pharma; it achieved ...

We recently compiled a list of the 10 Under-the-Radar Stocks with Massive Upside for 2025. In this article, we are going to ...

Maryland-based Novavax said that adding its adjuvant, which aims to boost the body’s immune response, did enhance the vaccine’s effectiveness. Novavax has received funding from Operation Warp ...

A further milestone came in 1998 in Uppsala, with the development of adjuvants for veterinary use and for humans after that. By 2013, European Novavax AB was acquired by the US Novavax Inc ...

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced progress in Q4 2024 advancing its corporate growth strategy through ...

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced progress in Q4 2024 advancing its corporate growth strategy through its ...

This makes it worthwhile to examine what the stock has in store. Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced progress ...

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced progress in Q4 2024 advancing its corporate growth strategy through its ...